title: NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
authors.affiliation: National Institute for Health and Clinical Excellence, London, UK.
authors.forename: Kay
authors.initials: K
authors.lastname: Nolan
authors.affiliation: National Institute for Health and Clinical Excellence, London, UK.
authors.forename: Helen
authors.initials: H
authors.lastname: Knight
authors.affiliation: National Institute for Health and Clinical Excellence, London, UK.
authors.forename: Peter
authors.initials: P
authors.lastname: Clark
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003091:Colistin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000188:drug therapy; D016903:Drug Monitoring / Q000379:methods; D004359:Drug Therapy, Combination; D058995:Dry Powder Inhalers; D006801:Humans; D017410:Practice Guidelines as Topic; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D012129:Respiratory Function Tests; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology; D013222:State Medicine; D014031:Tobramycin / Q000008:administration & dosage*; D006113:United Kingdom
chemical_list: D000900:Anti-Bacterial Agents; C004691:colistinmethanesulfonic acid; D014031:Tobramycin; D003091:Colistin